Cancer, with all its wiles, has figured out how to withstand science’s best efforts by tapping a secret genetic arsenal. One company aims to kill drug-resistant tumors by cutting off their resupply.
Scores of treatments work by targeting cancer-causing genes like EGFR and HER2. But the trickiest tumors have devised a way to replace the malignant genes by reaching into tiny circles of DNA floating inside cancer cells, allowing tumors to grow despite a pharmaceutical assault. At Boundless Bio, which just raised $46 million in venture funding, the idea is to knock out the backup DNA before cancer can reload.